Why Nasdaq-100 Inverse ETF SQQQ Is Diving

ProShares UltraPro Short QQQ ETF (NASDAQ: SQQQ) shares are trading lower by 3.97% to $18.40 Wednesday morning.

ProShares UltraPro Short QQQ ETF (NASDAQ:SQQQ) shares are trading lower by 3.97% to $18.40 Wednesday morning. Major indexes are higher after June CPI data showed softer-than-expected inflation.

For the unitiated, SQQQ is a popular, 3x-leveraged inverse ETF that tracks the Nasdaq-100.

What Happened?

U.S. CPI inflation in June decelerated more than anticipated, reinforcing investor expectations of a single rate hike by the Federal Reserve followed by a halt to its tightening cycle. The Bureau of Labor Statistics’ data reveals a drop in the annual inflation rate from 4% in May to 3% in June, slightly below the average economist forecast of 3.1%.

This marks the twelfth consecutive month of declining inflation and the lowest reading since March 2021…Read More

What Else?

SQQQ is primarily designed for short-term trading and market timing strategies. Some investors may use it as a tool to take advantage of anticipated market downturns or as a tactical way to implement short-term trading strategies based on their outlook for the Nasdaq-100 Index.

According to data from Benzinga Pro, SQQQ has a 52-week high of $42.44 and a 52-week low of $16.10.

Total
0
Shares
Related Posts
Read More

Myomo, Enzo Biochem And These 2 Stocks Under $2 Insiders Are Aggressively Buying

The Dow Jones closed lower by more than 600 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

CNTX

Read More

Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment In Ongoing Phase II Study Of BMF-219 In Adults With Type 2 Diabetes In Poster Presentation At WCIRDC

BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetesAt Week 26, 22 weeks after the last dose of BMF-219, participants in the 100

BMEA